Janssen Pharmaceutical Cos. has returned the rights to obesity/diabetes therapy HM12525A (JNJ-5111), a long-acting GLP/GCG analog to originator Hanmi Pharmaceutical Co. Ltd., after Phase II studies achieved their weight reduction targets, the primary evaluation indicator, but not their glycemic control goals for obese diabetics.
The South Korean firm was upbeat however. “Through the results of Phase II trials Janssen has conducted, the compound has...







